Wednesday, 16 June 2021
Home »
Health
,
Health news
,
IFTTT
,
NYT
» CureVac’s vaccine performed poorly in a clinical trial, in part because of virus variants.
CureVac’s vaccine performed poorly in a clinical trial, in part because of virus variants.
By BY CARL ZIMMER from NYT Health https://ift.tt/2S3JZhJ
0 comments:
Post a Comment